DexCom, Inc. (NASDAQ:DXCM) Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 0.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 635,596 shares of the medical device company's stock after purchasing an additional 3,996 shares during the period. California State Teachers Retirement System owned 0.16% of DexCom worth $49,430,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Congress Asset Management Co. boosted its holdings in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of DexCom during the 4th quarter valued at about $5,812,000. Fifth Third Bancorp raised its position in shares of DexCom by 21.5% during the 4th quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company's stock valued at $2,438,000 after buying an additional 5,553 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the 4th quarter valued at about $49,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter valued at about $454,000. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. Robert W. Baird decreased their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Mizuho began coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Citigroup restated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group upped their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $98.32.

DexCom Trading Up 1.3%

Shares of NASDAQ:DXCM traded up $1.10 during trading on Friday, reaching $85.96. 4,257,051 shares of the company were exchanged, compared to its average volume of 4,370,189. The firm has a market capitalization of $33.71 billion, a PE ratio of 60.11, a P/E/G ratio of 2.30 and a beta of 1.43. The business's fifty day simple moving average is $74.42 and its 200-day simple moving average is $78.57. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $121.47. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business's revenue was up 12.5% compared to the same quarter last year. During the same period last year, the business posted $0.32 earnings per share. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company's stock, valued at $10,002,636.06. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 83,110 shares of company stock valued at $6,103,505 over the last ninety days. 0.32% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.